Overview

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

Status:
Completed
Trial end date:
2020-03-15
Target enrollment:
0
Participant gender:
All
Summary
Chronic rhinosinusitis (CRS) affects up to 12.5% of the US population and has a significant disease burden. The recommended medical management of CRS includes large-volume, low-pressure saline lavage, systemic antibiotics, and intranasal corticosteroids (INCS). While the efficacy and safety of INCS are well-established for the long-term management of CRS, penetration of INCS beyond the nasal vestibule and into the paranasal sinuses is limited. The aim of this study is to evaluate the effectiveness of mometasone furoate large-volume, low-pressure nasal irrigation for surgery-naive CRS patients.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Mometasone Furoate
Criteria
Inclusion Criteria:

12-weeks or longer of two or more of the following signs and symptom consistent with CRS:

- mucopurulent drainage(anterior, posterior, or both)

- nasal obstruction (congestion)

- facial pain-pressure-fullness

- and decreased sense of smell

AND inflammation documented by one or more of the following findings:

- purulent mucus or edema in the middle meatus or ethmoid region

- radiographic imaging showing inflammation of the paranasal sinuses.

Exclusion Criteria:

- inability to speak or understand English

- nasal polyps

- history of nasal or sinus surgery

- comorbid mucociliary conditions

- dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma
and chronic obstructive pulmonary disease

- history of oral or systematic antibiotic use in the past 2 weeks

- history of allergy to MF or other topical steroids

- pregnant or breastfeeding

- participants with a baseline SNOT-22 score of 9 or less will be excluded due to
inability to achieve a minimally clinically improved difference pre- and
post-intervention.